R&D
GEXVal's Lead Program GXV-001 Receives FDA Rare Pediatric Disease DesignationNew!!
2026/11/18
GEXVal Inc. November 18, 2026 GEXVal's Lead Program GXV-001 Receives Rare Pediatric Disease Designation from t […]
GEXVal Receives Funding from a Parkinson’s Research Program at The Michael J. Fox Foundation
2025/2/14
GEXVal Inc.February 14, 2025 GEXVal Inc. (President & CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, […]
GEXVal Selected for AMED’s ‘Strengthening Program for Pharmaceutical Startup Ecosystem’
2024/12/16
GEXVal Inc.16 December, 2024 We are delighted to announce that GEXVal Inc.'s planned global Phase 2a Proof of […]
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia
2024/7/1
GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]
GEXVal Sponsors SLTBR 2024 35th Annual Meeting
2024/6/18
GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]

